Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

HOPA 2018 | Immunotherapy options for NSCLC: nivolumab, pembrolizumab or atezolizumab?

How do you decide on which drug to use when treating non-small cell lung cancer (NSCLC) patients in a second-line setting? Here, speaking at the Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Ross Camidge, MD, PhD, of University of Colorado, Aurora, CO addresses the question of how to choose between nivolumab, pembrolizumab and atezolizumab for the treatment of NSCLC.